Physician profile
Matthew Katz
NPI 1013395730
$68,107.89
in general payments reported to CMS, 2019-2025
22 companies · $7,726 in 2025
The $7,726 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25K · 2021: $15K · 2022: $5,506 · 2023: $12K · 2024: $2,606 · 2025: $7,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $3,022 · Travel and Lodging: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,367.07 |
| Food and Beverage | $3,021.63 |
| Travel and Lodging | $608.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $52,609.44 | 2020-2025 | General - Kidney Stone Disease, Lithovue, Lumenis Pulse 120h |
| Ambu A/S | $11,879.57 | 2022-2024 | |
| Ambu INC. | $1,790.09 | 2021-2025 | |
| Urogen Pharma, INC. | $583.42 | 2021-2025 | Jelmyto |
| Procept Biorobotics Corporation | $252.51 | 2021-2023 | Aquabeam Robotic System |
| Novo Nordisk INC | $165.40 | 2024 | Rivfloza |
| Abbott Laboratories | $146.92 | 2025 | Cardiomems, Assurity |
| Axonics, INC. | $146.92 | 2024 | Axonics, Bulkamid |
| Cook Medical LLC | $97.91 | 2025 | Zenith Alpha |
| Antares Pharma, INC. | $89.22 | 2022-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $46.34 | 2023 | Lokelma |
| Endo Pharmaceuticals INC. | $40.24 | 2021 | |
| Endo USA, INC. | $37.77 | 2025 | Xiaflex, Aveed |
| Edap Technomed INC | $37.43 | 2025 | |
| Angiodynamics, INC. | $29.85 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $27.48 | 2020 | |
| Dentsply Ih Ab | $24.89 | 2023 | Lofric |
| Medtronic, INC. | $23.53 | 2024 | Interstim |
| Sanofi-Aventis U.S. LLC | $23.15 | 2022 | |
| Millicent US INC | $20.10 | 2025 | Intrarosa |
| Coloplast Corp | $19.22 | 2021 | |
| Dentsply Ih INC. | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.